Un-siloed biomedical opportunities www.nature.com/articles/d41... Edith Heard, CEO of the Francis Crick Institute in London @crick.ac.uk, discusses the need to break down biomedical boundaries

1/4 Delighted (+relieved) our @natrevdrugdiscov.nature.com perspective on AI in R&D finally out. Channeling R. Solow: why do we see AI everywhere in biopharma except in the productivity statistics? As we write, evidence of its clinically relevant impact remains “disappointingly limited.”

The FDA recently approved the first orexin receptor agonist for narcolepsy nature.com/articles/d41... Oveporexton is anticipated to transform the treatment of this sleep disorder, and potential additional applications have led to the class being dubbed the GLP-1s of neuroscience

For readers interested in the opportunities and pitfalls for CAR-T therapies for autoimmune diseases, here's a recent comprehensive Review www.nature.com/articles/s41... rdcu.be/97VgTv2SaRTa

Roads and detours for CAR T cell therapy in autoimmune diseases - Nature Reviews Drug Discovery

Following on from its success in eradicating malignant B cells in cancer, chimeric antigen receptor (CAR) T cell therapy has been extended to treat autoimmune diseases. This Review discusses the precl...

nature.com

Novartis and Bristol Myers Squibb have paused their CAR-T trials for #lupus and other autoimmune diseases to review safety concerns. CAR-T remains experimental, and continued research is needed to understand its benefits and risks. Read the announcement: buff.ly/QJBbN7L

Solute carrier membrane transporters: emerging targets in CNS disorders www.nature.com/articles/s41... rdcu.be/uQeAYKzFg8Ua This new Review discusses targeting SLC transporters in neurodegenerative diseases, autism spectrum disorders and epilepsy

For readers interested in JAK inhibitors for autoimmmune diseases, such as Roivant's brepocitinib that has just been approved by the FDA for dermatomyositis, here's a review on pharmacological targeting of the JAK-STAT pathway nature.com/articles/s41... rdcu.be/rpNrcuDMf4ha

The FDA has approved brepocitinib as a TYK2/JAK1 inhibitor from Roivant/Priovant Huge shout out to the #PfizerChemistry team who discovered the molecule - it was a large project team and when I joined the mol had already been identified and… #ChemSky 1/…

Our September issue is live! Read about brain-shuttle biologics, targeting claudins in cancer, agonist antibody-based immunotherapies, autophagy modulation in cancer and more here nature.com/nrd/volumes/...

Towards precision psychiatry: initial foundations and future directions www.nature.com/articles/s41... rdcu.be/fCeOU This new Perspective discusses how to align drug development with underlying neural dysfunctions using patient-specific measures of brain function such as EEG

Towards precision psychiatry: initial foundations and future directions - Nature Reviews Drug Discovery

Drug discovery for psychiatric disorders is a slow and challenging process, driven in part by reliance on symptom-based diagnostic criteria that fail to capture the underlying disease biology. In thei...

nature.com

For neurologists who want to stay current, Springer Nature has a new resource made for you. Nature Briefing: Clinical Neurology brings together key clinical developments and research from leading journals in the field in a weekly newsletter. Sign up is free go.springernature.com/int1/briefin...

Sign up for Nature Briefing: Clinical Neurology

go.springernature.com

For readers interested in mRNA therapeutics, including neoantigen-based therapeutic cancer vaccines such as Moderna and Merck's intismeran autogene, here's a recent Review www.nature.com/articles/s41... rdcu.be/fBiGZ

An experimental mRNA vaccine allowed people with high-risk melanoma to live longer, cancer-free, in a large, closely watched trial, the pharmaceutical companies Moderna and Merck announced Wednesday.

Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning

Moderna and Merck say the experimental vaccine prevented the return and spread of the cancer in high-risk melanoma patients.

nyti.ms

In the wake of the FDA approval of Takeda's first-in-class orexin 2 receptor agonist oveporexton for narcolepsy last week, there is a burgeoning pipeline of orexin modulators for a range of central nervous system disorders nature.com/articles/d41...

Orexin receptor agonist secures landmark narcolepsy approval

As Takeda’s oveporexton (Orzeyful) becomes a first-in-class treatment for narcolepsy type 1, industry eyes broader indications for orexin receptor agonists.

nature.com

Oncolytic virus nabs FDA approval nature.com/articles/d41... Replimune’s vusolimogene oderparepvec (Tudriqev, also known as RP1) has received accelerated approval for use in combination with the PD-1 blocker nivolumab for advanced melanoma. It is the second oncolytic virus to reach the US market

For readers interested in targeted protein degradation, this Perspective in the August issue discusses safety considerations in the development of PROTAC and molecule glue drug candidates that recruit the E3 ligase cereblon www.nature.com/articles/s41... rdcu.be/fzgJJ

Orexin receptor agonist secures landmark narcolepsy approval nature.com/articles/d41... As Takeda’s oveporexton (Orzeyful) becomes a first-in-class treatment for narcolepsy type 1, industry eyes broader indications for orexin receptor agonists

Artificial intelligence in drug discovery — what it is, where we stand and the path forward nature.com/articles/s41... rdcu.be/fyUFz

For readers interested in 'in vivo' CAR-T therapies for cancer and autoimmune diseases, here's a comprehensive review from pioneers in the field nature.com/articles/s41... rdcu.be/fx2H3

In vivo chimeric antigen receptor (CAR)-T cell therapy - Nature Reviews Drug Discovery

In vivo chimeric antigen receptor (CAR)-T cell engineering uses targeted delivery systems to generate CAR-T cells directly in patients, bypassing ex vivo manufacturing. This Review examines emerging v...

nature.com

Johnson & Johnson announced collaboration with privately held Sail Biomedicines to develop CAR-T therapies for immune-mediated diseases, J&J said in a statement

J&J Gains Option to Buy Sail Biomedicines for $2.6 Billion

Johnson & Johnson announced a collaboration with Sail Biomedicines to develop CAR-T therapies for immune diseases and said it now has an exclusive option to acquire the closely held company.

bloom.bg

For readers interested in mRNA therapeutics, this Review discusses progress and lessons learned from candidates in clinical trials for applications including cancer immunotherapy, genome editing and in vivo CAR-T cell therapy www.nature.com/articles/s41... rdcu.be/fxNFo

Towards mRNA therapeutics 2.0 - Nature Reviews Drug Discovery

mRNA technology is being applied to develop a new generation of therapies for rare and common diseases. This Review discusses insights from clinical studies on mRNA-based therapeutics, including enzym...

nature.com

Our latest research highlight covers a paper in Nature on a novel RNA modification that could improve the characteristics of mRNA-based therapeutics www.nature.com/articles/d41...

Optimizing translation of therapeutic mRNAs

Discover the world’s best science and medicine | Nature.com

nature.com

Multispecific T-cell engagers that bind three or more targets on cancer and immune cells promise to address the shortcomings of their bispecific predecessors - find out more in this news story in our August issue www.nature.com/articles/d41...

Our August issue is live! Read about multispecific T-cell engagers for cancer, the design of small-molecule kinase inhibitors, the evolution of pharmacotherapy for obesity, safety considerations for targeted protein degraders and more here www.nature.com/nrd/volumes/...

Review @natrevdrugdiscov.nature.com Targeting T follicular helper cells for lifelong health www.nature.com/articles/s41...

Oral macrocyclic PCSK9 inhibitor secures FDA approval nature.com/articles/d41... Merck & Co.’s enlicitide has been approved to reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia

Oral macrocyclic PCSK9 inhibitor secures FDA approval

Discover the world’s best science and medicine | Nature.com

nature.com

For readers interested in drug discovery targeting GPCRs, this Review covers trends in the field: www.nature.com/articles/s41... rdcu.be/fwSqG and this Review covers opportunities from understanding of functional dynamics: www.nature.com/articles/s41... rdcu.be/fwSrj

Our latest Research Highlight covers a paper in Nature on the discovery of small-molecule inhibitors of β-arrestins, which are important transducers of signalling via G protein-coupled receptors (GPCRs) www.nature.com/articles/d41...

Small molecules stop β-arrestins

Discover the world’s best science and medicine | Nature.com

nature.com

Targeting T follicular helper cells for lifelong health nature.com/articles/s41... rdcu.be/fwdMi This new Review discusses therapeutic strategies to modulate T follicular helper (TFH) cells, which support B cell function to promote long-lasting antibody responses

Targeting T follicular helper cells for lifelong health - Nature Reviews Drug Discovery

T follicular helper (TFH) cells support B cell function to promote long-lasting antibody responses but are implicated in many diseases and undergo age-related changes. This Review explores emerging th...

nature.com